AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Hub24 Ltd has seen a significant increase in its share price, rising by 59.3% since the beginning of 2024. Established in 2007, Hub24 has rapidly emerged as a prominent player in the wealth management sector, offering platforms and software solutions for financial advice, superannuation, and investment management.
Hub24's core offerings include the HUB24 platform, Class, and myprosperity. The HUB24 platform caters to financial advisers and their clients, providing access to a diverse range of managed funds and investment products. Class, a leading software solution, assists with managing self-managed super funds (SMSFs), including portfolios, legal documentation, and compliance. Myprosperity enhances client interactions by offering portals for accountants and advisers, improving overall service and customer experience.
The company's commitment to excellence in service has been recognized in 2024. Hub24 was awarded Overall Best Platform in the Adviser Ratings Financial Advice Landscape Report and ranked first for Overall Satisfaction and Brand Image and Reputation in the 2024 Wealth Insights Platform Service Level Report.
ResMed CDI (ASX:RMD)
ResMed CDI has experienced a substantial decline of 74.1% from its 52-week low. Founded in 1989 by Peter Farrell in Australia and now headquartered in San Diego, California, ResMed is a leading provider of medical equipment, specifically cloud-connected continuous positive airway pressure (CPAP) machines designed for treating obstructive sleep apnea (OSA). While ResMed’s primary listing is on the NYSE, it is also listed on the ASX.
Operating globally with over 10,000 employees in more than 140 countries, ResMed is divided into two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care unit provides CPAP machines and other respiratory support devices. The SaaS unit offers software solutions that support durable and home medical equipment (DME/HME), contributing to out-of-hospital care.
ResMed’s expansive digital health network, driven by its cloud-connected devices, allows it to leverage data from its industry-leading hardware, such as masks and humidifiers, to improve patient outcomes and reduce overall healthcare costs.
Hub24 Ltd (ASX:HUB)
For growth companies like Hub24 Ltd, assessing the share price involves examining various valuation metrics. Currently, Hub24’s price-to-sales ratio stands at 14.16x, which is above its 5-year average of 11.61x. This indicates that the shares are trading at a higher multiple than in the past. However, it is important to consider multiple factors when evaluating a stock's valuation, as relying on a single metric may not provide a complete picture.
Both Hub24 Ltd and ResMed CDI have experienced notable movements in their share prices, reflecting significant developments in their respective sectors. Hub24’s impressive rise underscores its growing influence in the wealth management industry, while ResMed’s substantial decline highlights the challenges faced in the medical equipment sector.
